Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

Overview

About this study

Progesterone amplifies estrogen-stimulated Growth Hormone (GH) secretion in postmenopausal women. Preliminary data are sought to estimate statistical power for more detailed studies of this hypothesis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • women ages 50 to 80
  • postmenopausal as defined by: any combination of the following

    • Hormonally postmenopausal for 1 year
    • Lh greater than 15 IU/L, FSH greater than 30 IU/L
    • Total hysterectomy with oophorectomy greater than one year
    • Hysterectomy with ovaries preserved with hormone levels: Lh > 15 IU/L, FSH > 30 IU/L
  • Following laboratory results with normal range, unless PI approves out of range values.
  • BMI 18 to 35

Exclusion Criteria:

  • structural hypothalamo-pituitary-gonadal disease
  • endocrinopathy (diseases involving the following organs pituitary, thyroid, adrenals, ovaries, testes and pancreas), other than primary thyroid failure receiving replacement
  • recent (within 2 weeks) estrogen, progestin, anabolic steroid or glucocorticoid use
  • clinically significant ECG abnormality as determined by study team physicians
  • obstructive uropathy
  • history of a stroke
  • history of MI or angina
  • acute or chronic systemic disease
  • recent transmeridian travel (traversing more than 3 time zones within 7 days of admission)
  • current night shift work
  • concurrent use of neuropsychiatric medications
  • alcohol or drug abuse, current and within 2 years
  • history of depression, psychosis, or mania
  • weight gain or loss (2 kg or more in 3 weeks)
  • BMI > 35 kg/m2
  • anemia, hemoglobin less than 12.5 g/dl
  • abnormal hepatorenal function, creatinine outside normal range, ALT greater than two times normal range
  • biochemical and chemistry lab results out of physician acceptable range
  • history of deep-vein thrombophlebitis
  • history of Congestive Heart Failure, cardiac arrhythmias, and medications used to treat cardiac arrhythmias
  • known allergy to estradiol valerate, castor oil or sesame oil
  • history of smoking within the last 2 years
  • untreated gall bladder disease
  • lack of voluntary, written informed consent
  • history of carcinoma excluding localized basal cell or squamous cell, including women with known, suspected or history of breast cancer
  • not clinically postmenopausal
  • women with allergies to nuts will not be enrolled in the study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Johannes Veldhuis, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20141839

Mayo Clinic Footer